Literature DB >> 21511293

Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer.

Takeo Kosaka1, Akira Miyajima, Suguru Shirotake, Eriko Suzuki, Eiji Kikuchi, Mototsugu Oya.   

Abstract

PURPOSE: There are still few effective therapeutic options for advanced prostate cancer. One of the most troublesome aspects of prostate cancer is that androgen dependent prostate cancer inevitably progresses to highly aggressive, life threatening castration resistant prostate cancer after androgen ablation therapy. To our knowledge it remains unknown how sensitivity to docetaxel changes during progression to more aggressive castration resistant prostate cancer under androgen ablation.
MATERIALS AND METHODS: We investigated sensitivity to docetaxel and phosphorylated Akt status in C4-2 and C4-2AT6 cells established at our institution.
RESULTS: C4-2AT6 cells established under androgen ablation conditions for 6 months showed significantly higher resistance to docetaxel than C4-2 cells in vivo and in vitro. Resistance was accompanied by increased phosphorylated Akt. In C4-2AT6 cells phosphorylated Akt activity was significantly up-regulated by docetaxel in a dose dependent manner. After treatment with docetaxel and a phosphatidylinositol 3-kinase/Akt inhibitor the sensitivity of C4-2AT6 cells to docetaxel markedly increased through enhanced apoptotic death.
CONCLUSIONS: Findings indicated that up-regulation of phosphorylated Akt during androgen ablation and its further activation by docetaxel explains at least in part the resistance to docetaxel and progression to castration resistant prostate cancer under androgen ablation conditions.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21511293     DOI: 10.1016/j.juro.2011.02.016

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  25 in total

1.  Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.

Authors:  Yezi Zhu; Chengfei Liu; Cameron Armstrong; Wei Lou; Amandeep Sandher; Allen C Gao
Journal:  Clin Cancer Res       Date:  2015-05-20       Impact factor: 12.531

2.  A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.

Authors:  Kevin D Courtney; Judith B Manola; Aymen A Elfiky; Robert Ross; William K Oh; Jeffrey T Yap; Annick D Van den Abbeele; Christopher W Ryan; Tomasz M Beer; Massimo Loda; Carmen Priolo; Philip Kantoff; Mary-Ellen Taplin
Journal:  Clin Genitourin Cancer       Date:  2014-10-22       Impact factor: 2.872

3.  Potent increased risk of the initiation of DNA replication in human prostate cancer with the use of 5α-reductase inhibitors.

Authors:  Takeo Kosaka; Yota Yasumizu; Yasumasa Miyazaki; Akira Miyajima; Eiji Kikuchi; Mototsugu Oya
Journal:  Am J Clin Exp Urol       Date:  2014-07-12

4.  Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.

Authors:  Yezi Zhu; Chengfei Liu; Nagalakshmi Nadiminty; Wei Lou; Ramakumar Tummala; Christopher P Evans; Allen C Gao
Journal:  Mol Cancer Ther       Date:  2013-07-16       Impact factor: 6.261

5.  Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells.

Authors:  I Tsaur; J Makarević; E Juengel; M Gasser; A-M Waaga-Gasser; M Kurosch; M Reiter; S Wedel; G Bartsch; A Haferkamp; C Wiesner; R A Blaheta
Journal:  Br J Cancer       Date:  2012-07-10       Impact factor: 7.640

6.  Elevated prx1 provides resistance to docetaxel, but is not associated with predictive significance in lung cancer.

Authors:  Ki Eun Hwang; Chul Park; Chang Hwan Seol; Yu Ri Hwang; June Seong Hwang; Jae Wan Jung; Keum Ha Choi; Eun Taik Jeong; Hak Ryul Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-08-30

Review 7.  Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer?

Authors:  Takeo Kosaka; Akira Miyajima; Mototsugu Oya
Journal:  Front Oncol       Date:  2014-09-16       Impact factor: 6.244

8.  Subverting ER-stress towards apoptosis by nelfinavir and curcumin coexposure augments docetaxel efficacy in castration resistant prostate cancer cells.

Authors:  Aditi Mathur; Zakaria Y Abd Elmageed; Xichun Liu; Mikhail L Kostochka; Haitao Zhang; Asim B Abdel-Mageed; Debasis Mondal
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

9.  TUGDA: task uncertainty guided domain adaptation for robust generalization of cancer drug response prediction from in vitro to in vivo settings.

Authors:  Rafael Peres da Silva; Chayaporn Suphavilai; Niranjan Nagarajan
Journal:  Bioinformatics       Date:  2021-05-17       Impact factor: 6.937

10.  Human castration resistant prostate cancer rather prefer to decreased 5α-reductase activity.

Authors:  Takeo Kosaka; Akira Miyajima; Hirohiko Nagata; Takahiro Maeda; Eiji Kikuchi; Mototsugu Oya
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.